Spanish Translation and Linguistic Validation of the Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Spanish Translation and Linguistic Validation of the Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Background:
Objectives:
- To test a Spanish version of the PRO-CTCAE questionnaire.
Eligibility:
- Latinos at least 18 years of age who are having or have recently finished cancer treatments and whose main language is Spanish
Design:
This study describes a study to assess a newly created Spanish version of the National Cancer Institute s (NCI s) patient toxicity questionnaire, the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), via semi-structured interviews among Spanish-speaking patients with cancer in the United States.
Background:
The NCI s PRO-CTCAE initiative has developed and preliminarily validated a library of items in English intended for patient self-reporting of treatment toxicity and symptoms during participation in cancer clinical trials. These items have also been translated into Spanish, using a methodology consistent with internationally agreed-upon guidelines for developing global translations.
Objective:
To linguistically validate a Spanish-language version of PRO-CTCAE symptom items to assure that they are culturally, semantically, and linguistically proficient to the native Spanish-speaking population with cancer in the United States.
Eligibility:
Research participants must be (i) 18 years or older; (ii) able to provide informed consent; (iii) currently undergoing systemic cancer treatment or immediately post-treatment; (iv) speak Spanish as their primary language.
Design:
Two rounds of PRO-CTCAE questionnaire administration followed by cognitive interviews will be conducted with Spanish speakers residing in the US. Between 40-60 interviews will be conducted in the first round, and up to 20 additional interviews will be conducted in an optional second round; total accrual will be 80 participants. Participating sites have been selected to assure access to participants from a range of Spanish-speaking countries of origin, and those with lower levels of educational attainment and acculturation.
Cognitive interviewing methodology provides an approach to determining that language adaptations produced through forward and back translation are conceptually equivalent to the English source document, and cross-culturally valid. Data derived from cognitive interviewing permit a conclusion that item meanings are qualitatively equivalent after translation and across individuals, and permit refinement, as necessary, to render terminologies and phrasing that are culturally acceptable and relevant to the target population.
A large number of PRO-CTCAE symptom items will be evaluated in this study, and in addition, several of the items are gender-specific. To minimize patient burden and ensure that the item pool is uniformly evaluated relative to participant gender, education, acculturation and country of origin, items have been distributed across four questionnaires, each matched with a tailored interview schedule. Each participant will complete one questionnaire and participate in one interview.
Interviewers are Bachelor- and Masters-prepared research staff who are bilingual and have experience with cognitive interviewing in clinical research and/or cancer treatment settings.
Interview summaries will be produced in English by each interviewer; audiotapes will be reviewed as necessary. These summaries together with relevant field notes will be assembled into a report, and used to further refine the translated PRO-CTCAE items.
EXCLUSION CRITERIA: